NewAmsterdam Pharma Company N.V. (NAMS)

Market Cap	3.61B
Revenue (ttm)	35.24M
Net Income (ttm)	-221.07M
Shares Out	113.39M
EPS (ttm)	-1.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	590,806
Open	32.57
Previous Close	32.69
Day's Range	31.47 - 32.83
52-Week Range	14.06 - 42.00
Beta	0.07
Analysts	Strong Buy
Price Target	46.40 (+45.55%)
Earnings Date	Feb 25, 2026

About NAMS

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in N...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 68
• Stock Exchange: NASDAQ
• Ticker Symbol: NAMS
• Website: https://www.newamsterdampharma.com

Financial Performance

In 2024, NAMS's revenue was $45.56 million, an increase of 223.37% compared to the previous year's $14.09 million. Losses were -$241.60 million, 36.5% more than in 2023.

Analyst Summary

According to 10 analysts, the average rating for NAMS stock is "Strong Buy." The 12-month stock price target is $46.4, which is an increase of 45.55% from the latest price.

Price Target

$46.4

(45.55% upside)

Analyst Consensus: Strong Buy